NEW YORK – Twist Bioscience and Abcam said on Tuesday that they have entered into a licensing agreement for antibodies in diagnostic and research applications.
Under the terms of the deal, Abcam will license a proprietary Twist single-domain (VHH) phage library for antibody discovery, development, and commercialization for diagnostic and research applications. Twist grants Abcam the right to engage in research and development activities using the synthetic antibody library. Abcam has the option to nominate, license, and commercialize antibody sequences for diagnostic and research use in return for license fees and commercial milestone payments. Twist will retain rights to the same sequences for therapeutic application.
Other details were not disclosed.
The deal "allows us to access the research and diagnostic market," Twist cofounder and CEO Emily Leproust said in a statement, and "lays the foundations for a long-term collaboration with Abcam to drive new commercial opportunities."
In January 2021, South San Francisco, California-based Twist signed a licensing agreement with Serotiny to provide custom DNA libraries that encode chimeric antigen receptors.
Last month, Abcam signed a strategic partnership with Alamar Biosciences for proteomics research.